FDA (CBER)
GUIDANCE FINAL
Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry
Published: 11/3/2026Detected: 11/2/2026
Summary preview
Recommends risk-reduction measures to minimize the likelihood of transfusion-transmitted hepatitis B virus (HBV) in blood and blood components.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
safety
#transfusion-transmitted hepatitis B
#HBV
#blood components
#donor screening
#infectious disease testing
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026
- Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method9/16/2026